Sep 14, 2023 / 10:00AM GMT
Sarah Jennifer Howell - Arecor Therapeutics plc - CEO & Director
So good morning, everybody. It's a pleasure to be here. Thank you for taking the time to join us today. It's lovely to see so many faces in the room, and welcome to those of you that are joining us online. And I think as most of you know, my name is Sarah Howell, I'm the CEO of Arecor Therapeutics and joined today by Susan Lowther, our CFO, and we'll be talking you through the interim results for the 6 months ending 30th of June 2023.
Now for -- I should draw your attention. I shouldn't forget this. So our customary legal notice. So I know many of you know and very familiar with Arecor now. But for those of you that are new here today, there's a few new faces in the room, and I'm sure there are online today. I'm going to just walk through a very high-level introduction to the business and really how we're creating value through our pipeline. So Arecor, we're very much focused on transforming patient care by enhancing existing therapeutic medicines so they're safer, more effective and easier to use. And we do this by leveraging
Half Year 2024 Arecor Therapeutics PLC Earnings Call Transcript
Sep 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers